• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

3rd time's the charm? PTC will get another chance to keep Translarna's European...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 20, 2024 at 06:12: PM
via Four months after Europe's drug reviewers doubled down and recommended the withdrawal of PTC Therapeutics' Translarna for lack of efficacy, the drug's regulatory odyssey is taking yet another turn.

article source
 

<



Similar threads

cafead
Mesoblast&#039;s CEO takes 30% pay cut to fund 3rd shot at cell therapy approval
Replies
0
Views
216
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
3rd patient death potentially tied to Eisai&#039;s Alzheimer&#039;s drug reported
Replies
0
Views
217
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ASH: Bristol&#039;s 3rd-line Abecma data didn&#039;t make the trip to New Orleans. Is it...
Replies
0
Views
178
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca&#039;s Ultomiris scores its 3rd FDA approval, setting up market clash with argenx
Replies
0
Views
96
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Pfizer&#039;s $130M Lyme disease vaccine advances to phase 3 after 3rd shot shown to...
Replies
0
Views
119
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote